Comparisons of the Intraocular Tissue Distribution,Pharmacokinetics,and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration

Abstract

Access of recombinant proteins to the retina following intravitreal administration is poorly understood. A study was conducted in male Rhesus monkeys (15 to 28 mo of age; 2.8-3.3 kg) in order to compare the intraocular tissue distribution, pharmacokinetics, and safety of ¹²⁵Iodine (I)-labeled full-length humanized rhuMAb HER2 antibody (148 kD) and of ¹²⁵I-labeled humanized rhuMAb vascular endothelial growth factor Fab antibody (48.3 kD) following bilateral bolus intravitreal injection on day 0 (5 animals/group). The dose administered to each eye was 25 μg (9-10 μCi) in 50 μl. Animals were euthanatized on day 0 (1 hr postdose) and on days 1, 4, 7, and 14. Safety assessment included direct ophthalmoscopy, intraocular pressure measurements, clinical observations, body weight, and hematology and clinical chemistry panels. Blood and vitreous samples were collected daily (blood only) and at necropsy for pharmacokinetics and analysis for antibodies to the test materials; the ocular tissue distribution of the test material was evaluated by microautoradiography. All animals completed the study. Microautoradiography demonstrated that the full-length antibody did not penetrate the inner limiting membrane of the retina at any of the time points examined. In contrast, the Fab antibody fragment diffused through the neural retina to the retinal pigment epithelial layer at the 1-hr time point and persisted in this location for up to 7 days. Systemic exposure to test material was low but variable: the highest plasma concentration of the full-length antibody was 20.3 ng/ml, whereas plasma concentrations for the Fab antibody remained below the limit of quantitation (i.e., <7.8 ng/ml). An immune response to the test material was not evident in either treatment group. The half-life in vitreous was 5.6 days for the full-length antibody and 3.2 days for the Fab antibody. The shorter intravitreal half-life of the Fab antibody is related to its smaller size and its significant diffusion through the retinal layers. The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions.

Keywords

Recombinant protein monoclonal antibody retinal drug delivery pharmacokinetics microautoradiography intravitreal intraocular immunogenicity

References

Adamis AP , Shima DT , Tolentino M. , Gragoudas E. , Ferrara N. , Folkman J. , D'Amore PA , and Miller JW (1996). Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch. Ophthalmol. 114: 66-71.

Aiello LP , Avery R. , Arrigg R. , Keyt B. , Jampel H. , Shah S. , Pasquale L. , Thieme H. , Iwamoto M. , Park JE , Nguyen H. , Aiello LM , Ferrara N. , and King GL (1994). Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331: 1480-1487.

Bermingham-McDonogh O. , McCabe K. , and Reh T. (1996). Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina. Development 122: 1427-1438.

Bressler N. , Fine S. , and Bressler S. (1994). Angiographic interpretation of classic and occult choroidal neovascularization. In: Medical and Surgical Retina , H Lewis and S Ryan (eds). Mosby, St. Louis , pp. 3-11.

Ferrara N. , Carver-Moore K. , Chen H. , Dowd M. , Lu L. , O'Shea KS , Powell-Braxton L. , Hillan KJ , and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature ( Lond.) 380: 439-442.

Ferrara N. and Davis-Smyth T. (1997). The biology of vascular endothelial growth factor . Endocr. Rev. 18: 4-25.

Folkman J. and Shing Y. (1992). Angiogenesis. J. Biol. Chem. 267: 10931-10934.

Garner A. (1994). Vascular diseases. In: Pathobiology of Ocuiar Diseases. A Dynamic Approach, A Garner and GK Klintworth (eds). Marcel Dekker, New York, pp. 1625-1710.

Hunter W. and Greenwood F. (1962). Preparation of 131-Iodine labeled human growth hormone of high specific activity. Nature ( Lond.) 194: 495-496.

10.

Kim KJ , Li B. , Winer J. , Armanini M. , Gillett N. , Phillips HS , and Ferrara N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature ( Lond.) 362: 841-844.

11.

Kinsey V. , Grant M. , and Cogan D. (1942). Water movement and the eye. Arch. Ophthalmol. 27: 242-252.

12.

Krummen L. , Moore A. , Woodruff T. , Covello R. , Taylor R. , Working P. , and Mather J. (1994). Localization of inhibin and activin binding sites in the testis during development by in situ ligand binding. Biol. Reprod. 50: 734-744.

13.

Lopez PF , Sippy BD , Lambert HM , Thach AB , and Hinton DR (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neo-vascular membranes. Investig. Ophthalmol. Vis. Sci. 37: 855-868.

14.

Maurice D. ( 1959). Protein dynamics in the eye studies with labeled proteins. Am. J. Ophthalmol. 47: 361-367.

15.

Metrikin D. , Wilson C. , Berkowitz B. , Lam M. , Wood G. , and Peshock R. (1995). Measurement of blood-retinal barrier breakdown in endotoxin-induced endophthalmitis. Investig. Ophthalmol. Vis. Sci. 36: 1361-1370.

16.

Mordenti J. , Thomsen K. , Licko V. Berleau L. , Kahn J. , Cuthbertson R. , Duenas E. , Ryan A. , Schofield C. , Berger T. , Meng Y. , and Cleland J. (1999). Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol. Sci. (in press).

17.

Murata T. , Nakagawa K. , Khalil A. , Ishibashi T. , Inomata H. , and Sueishi K. (1996). The temporal and spatial vascular endothelial growth factor expression in retinal vasculogenesis of rat neonates. Lab. Invest. 74: 68-77.

18.

Pe'er J. , Shweiki D. , Itin A. , Hemo I. , Gnessin H. , and Keshen E. (1995). Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72: 638-645.

19.

Press W. , Flannery B. , Teukolsky S. , and Vetterling W. (1988). Numerical Recipes in C. Cambridge University Press, Cambridge, United Kingdom.

20.

Reilly R. , Sandhu J. , Alvarez-Diez T. , Gallinger S. , Kirsh J. , and Stern H. (1995). Problems of delivery of monoclonal antibodies . Clin. Pharmacokinet. 28: 126-142.

21.

Saunders L. and Rubin L. (1975). Postmortem techniques. In: Ophthalmic Pathology of Animals. S. Karger, New York, pp. 244-253.

22.

Slatter D. (1981). Glaucoma. In: Fundamentals of Veterinary Ophthalmology, D Slatter (ed). W. B. Saunders, Philadelphia, pp. 455-457.

23.

Smelser G. , Ishikawa T. , and Pei Y. (1965). Electron microscopic studies of intra-retinal spaces: Diffusion of particulate materials. In: Eye Structure , J Rohen (ed). Schattauer-Verlag , Stuttgart, pp. 109-120.

24.

Wagner J. (1976). Linear pharmacokinetic equations allowing direct calculations of many needed pharmacokinetic parameters from coefficients and exponents of poly-exponential equations which have been fitted to data. J. Pharmacokinet. Biopharm. 4: 443-467.